SK116294A3 - Recombinant human hiv-antibodies, cassette for expression, host cell and pharmaceutical agent against hiv - Google Patents

Recombinant human hiv-antibodies, cassette for expression, host cell and pharmaceutical agent against hiv Download PDF

Info

Publication number
SK116294A3
SK116294A3 SK1162-94A SK116294A SK116294A3 SK 116294 A3 SK116294 A3 SK 116294A3 SK 116294 A SK116294 A SK 116294A SK 116294 A3 SK116294 A3 SK 116294A3
Authority
SK
Slovakia
Prior art keywords
hiv
antibody
chain
neutralizing
recombinant human
Prior art date
Application number
SK1162-94A
Other languages
English (en)
Slovak (sk)
Inventor
Emilio A Emini
Anthony J Conley
George E Mark
L Johnson
David S Pfarr
Original Assignee
Merck & Co Inc
Med Immune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Med Immune Inc filed Critical Merck & Co Inc
Publication of SK116294A3 publication Critical patent/SK116294A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1162-94A 1992-04-01 1993-03-23 Recombinant human hiv-antibodies, cassette for expression, host cell and pharmaceutical agent against hiv SK116294A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86170192A 1992-04-01 1992-04-01
PCT/US1993/002629 WO1993019785A1 (fr) 1992-04-01 1993-03-23 Anticorps monoclonaux humains recombines neutralisant le vih destines a prevenir et a traiter l'infection due au vih

Publications (1)

Publication Number Publication Date
SK116294A3 true SK116294A3 (en) 1996-11-06

Family

ID=25336532

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1162-94A SK116294A3 (en) 1992-04-01 1993-03-23 Recombinant human hiv-antibodies, cassette for expression, host cell and pharmaceutical agent against hiv

Country Status (19)

Country Link
EP (1) EP0577243A3 (fr)
JP (1) JPH06217791A (fr)
KR (1) KR950700761A (fr)
CN (1) CN1081716A (fr)
AU (2) AU3928593A (fr)
BG (1) BG99074A (fr)
CA (1) CA2093099A1 (fr)
CZ (1) CZ239694A3 (fr)
FI (1) FI944561L (fr)
HU (1) HUT70461A (fr)
IL (1) IL105145A0 (fr)
MX (1) MX9301858A (fr)
NO (1) NO943653L (fr)
NZ (1) NZ251582A (fr)
RU (1) RU94045907A (fr)
SK (1) SK116294A3 (fr)
WO (1) WO1993019785A1 (fr)
YU (1) YU22693A (fr)
ZA (1) ZA932308B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2220114T3 (es) * 1998-10-30 2004-12-01 Novozymes A/S Variantes de proteinas poco alergenicas.
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
JP4922613B2 (ja) * 2003-02-20 2012-04-25 一般財団法人化学及血清療法研究所 モノクローナル抗体製剤の奏効性を向上させる方法
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー Ｖ３ループに改変を有するｈｉｖｅｎｖタンパク質
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
WO2015117008A2 (fr) * 2014-01-31 2015-08-06 The Rockefeller University Anticorps anti-vih de neutralisation large et épitope associé
JP6522732B2 (ja) * 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
EP4007605A4 (fr) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. Anticorps anti-fcrn et leurs procédés d'utilisation
WO2021227138A1 (fr) * 2020-05-09 2021-11-18 江苏省疾病预防控制中心(江苏省公共卫生研究院) Anticorps monoclonal du nouveau coronavirus, ou partie de liaison à l'antigène de celui-ci
CN118666967B (zh) * 2024-03-06 2025-03-28 广东医保药业有限公司 多肽及其与头孢噻肟舒巴坦的组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853779T2 (de) * 1987-05-29 1995-09-07 Baylor College Medicine Hiv-1 neutralisierende monoklonale antikörper.
EP0311228A3 (fr) * 1987-10-09 1990-05-02 Repligen Corporation Polypeptides recombinants et leur utilisation, y compris un diagnostic pour le virus du SIDA
WO1990015078A1 (fr) * 1989-06-05 1990-12-13 Scott Charles F Jr ANTICORPS MONOCLONAUX HUMAINS DE LA gp 120 DU VIH-1¿MN?
EP0535154A4 (en) * 1990-06-15 1993-12-01 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
EP0624193A1 (fr) * 1992-01-29 1994-11-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aamp-1, une proteine ayant des homologies locales avec les proteines env et nef de l'hiv-1

Also Published As

Publication number Publication date
EP0577243A3 (fr) 1994-11-02
FI944561A7 (fi) 1994-09-30
RU94045907A (ru) 1996-11-10
FI944561A0 (fi) 1994-09-30
NZ251582A (en) 1997-07-27
JPH06217791A (ja) 1994-08-09
FI944561L (fi) 1994-09-30
YU22693A (sh) 1997-01-08
BG99074A (bg) 1995-11-30
CA2093099A1 (fr) 1993-10-02
AU658987B2 (en) 1995-05-04
CZ239694A3 (en) 1995-07-12
KR950700761A (ko) 1995-02-20
HU9402824D0 (en) 1994-11-28
IL105145A0 (en) 1993-07-08
MX9301858A (es) 1994-03-31
EP0577243A2 (fr) 1994-01-05
AU3928593A (en) 1993-11-08
CN1081716A (zh) 1994-02-09
HUT70461A (en) 1995-10-30
NO943653D0 (no) 1994-09-30
NO943653L (no) 1994-11-30
WO1993019785A1 (fr) 1993-10-14
AU3563093A (en) 1993-10-07
ZA932308B (en) 1994-09-30

Similar Documents

Publication Publication Date Title
SK116294A3 (en) Recombinant human hiv-antibodies, cassette for expression, host cell and pharmaceutical agent against hiv
US20120269821A1 (en) Hiv-1 antibodies
US20200377577A1 (en) Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
US5665569A (en) HIV immunotherapeutics
KR100304333B1 (ko) 재조합의사람화된항-사람면역결핍바이러스항체
US20110212106A1 (en) Hiv-1 neutralizing antibodies and uses thereof
AU2019293530B2 (en) Anti-L1CAM antibodies and uses thereof
KR100251823B1 (ko) 사람 면역 결핍 바이러스(hiv) 감염의 면역치료용 모노클로날 항체
EP1373318A2 (fr) Anticorps humains, monoclonaux, neutralisants contr vih-1, leur production et utilisations
Okamoto et al. In SCID-hu mice, passive transfer of a humanized antibody prevents infection and atrophic change of medulla in human thymic implant due to intravenous inoculation of primary HIV-1 isolate
US20150239961A1 (en) Adcc-mediating antibodies, combinations and uses thereof
Matsushita et al. Characterization of a mouse/human chimeric monoclonal antibody (Cβ1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein
CA2122044C (fr) Immunotherapie anti-vih
RU2134724C1 (ru) Гуманизированное антитело и способ его получения, полинуклеотид (варианты), гибридомная клеточная линия (варианты)
KR100282576B1 (ko) 사람 면역 결핍 바이러스 면역치료제
Major et al. Construction and characterization of chimeric and humanized forms of a broadly neutralizing monoclonal antibody to HIV-1
KR20260025097A (ko) HIV Env 상의 CD4 결합 부위를 표적으로 하는 광범위 중화 항체
WO2025049708A1 (fr) Anticorps neutralisants humains ciblant l'env du vih
Ramirez Valdez Identification, isolation and characterization of monoclonal antibodies against HIV-1
AU2002241965A1 (en) Neutralizing human monoclonal antibodies against HIV-1, their production and uses